These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37819840)

  • 1. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017.
    Baker MC; Weng Y; Fairchild R; Ahuja N; Rohatgi N
    JAMA Netw Open; 2021 Jun; 4(6):e2110268. PubMed ID: 34081140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.
    Haar GS; Vasudevan A; Curtain CM; van Langenberg DR
    Res Social Adm Pharm; 2021 Aug; 17(8):1420-1425. PubMed ID: 33129684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
    Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
    J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
    Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
    World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.
    Shehab M; Zurba Y; Al Abdulsalam A; Alfadhli A; Elouali S
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes for Standardized Home and Hospital-Based Infusions of Infliximab for Children With Inflammatory Bowel Disease.
    Gupta SR; Bricker J; Boyle BM; Maltz RM; Michel HK; Dotson JL
    J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):776-781. PubMed ID: 36930973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
    Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives.
    Kochar B; Jiang Y; Chen W; Bu Y; Barnes EL; Long MD
    Crohns Colitis 360; 2021 Jul; 3(3):otab063. PubMed ID: 34805985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Same Day Infusion of Iron Therapy Is Associated With No Increased Risk for Adverse Events Among Patients Receiving Biological Infusions for Inflammatory Bowel Disease.
    Reddy S; Shore B; Abramson L; Herfarth HH; Barnes EL
    J Clin Gastroenterol; 2022 Oct; 56(9):e318-e322. PubMed ID: 35862033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
    Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.
    Shehab M; Alrashed F; Alfadhli A
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A home infliximab infusion program.
    Condino AA; Fidanza S; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.